Sample Page
Author:
BioVersys
Posted Date:
April 16, 2026
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BioVersys
April 16, 2026
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
BioVersys
April 15, 2026
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
BioVersys
April 13, 2026
BioVersys Strengthens Ansamycin Platform and NTM Research Through Collaboration and License Agreement with Hackensack Meridian Health
BioVersys
March 31, 2026
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
BioVersys
March 18, 2026
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
BioVersys
March 16, 2026
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis
BioVersys
March 12, 2026
BioVersys to Report Its Full Year 2025 Financial Results, Provide a Business Update and Host a Conference Call
BioVersys
March 5, 2026
BioVersys Announces Publication of BV100 Phase 1 Clinical Data in Journal of Antimicrobial Agents and Chemotherapy
BioVersys
March 4, 2026
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine
BioVersys
February 19, 2026
